# A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

> **NCT01122875** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MFGR1877S

## Key facts

- **NCT ID:** NCT01122875
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122875, "A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01122875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*